Capsaicin 0.25 MG/ML / menthol 15 MG/ML Topical Cream — RxCUI 2583630
RxNorm drug concept · Semantic clinical drug
RxCUI 2583630
Semantic clinical drug · SCD
● Current RxNorm concept 2 FDA products
2 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI2583630
Official nameCapsaicin 0.25 MG/ML / menthol 15 MG/ML Topical Cream
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known ascapsaicin 0.025 % / menthol 1.5 % Topical Cream
FDA products mapped2
Package NDCs mapped2
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Capsaicin Topical: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Yes, that burning or warming feeling is expected and is actually part of how it works. Capsaicin activates the same heat-sensing nerve endings that cause pain, so you feel that war...
- Why does capsaicin make my skin burn — is that normal?
- Please don't — that combination can cause serious burns. Heat sources like heating pads or hot water bottles significantly increase the risk when used alongside capsaicin. For the...
- Can I put a heating pad on after applying it to help with the pain more?
🕸️ Concept Web — How Capsaicin 0.25 MG/ML / menthol 15 MG/ML Topical... Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Capsaicin 0.25 MG/ML / menthol 15 MG/ML Topical Cream
RxCUI 2583630 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 3
The active substance itself — no strength, form, or brand attached yet.
-
Capsaicin
1992IN -
Menthol
6750IN -
Capsaicin / menthol
1007122MIN
-
Capsaicin
-
Dose forms 4
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Capsaicin / menthol Topical Cream
379012SCDF -
Capsaicin / menthol Topical Product
1155436SCDG -
Topical Cream
316982DF -
Topical Product
1151122DFG
-
Capsaicin / menthol Topical Cream
-
Clinical & branded drugs 2
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Capsaicin 0.25 MG/ML
340074SCDC -
Menthol 15 MG/ML
331743SCDC
-
Capsaicin 0.25 MG/ML
Showing up to 8 concepts per family — 9 of 9 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Capsaicin 0.25 MG/ML
SCDC · 340074 -
Menthol 15 MG/ML
SCDC · 331743 -
Capsaicin / menthol Topical Cream
SCDF · 379012 -
Capsaicin / menthol Topical Product
SCDG · 1155436
📦 FDA Products & Package NDCs
2 products · 2 package NDCs
2 package NDCs map to RxCUI 2583630 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 14448-0316-00 | 227 g in 1 JAR (14448-316-00) | BLUE SPRING Foot and Leg Comfort Cream with Pain Relief | BLUE SPRING WELLNESS, L.L.C. | 2021-10-25 |
| 83591-0417-00 | 237 mL in 1 JAR (83591-417-00) | EMU THERAPY Red Hot Pepper Pain Relief Cream | ACA MANAGEMENT LLC | 2023-08-08 |
Observed labelers:
ACA MANAGEMENT LLC (1) ·
BLUE SPRING WELLNESS, L.L.C. (1)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.